Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
trans-3,4-Difluorocinnamic acid → 1-[(e)-3-(3,4-Difluoro-phenyl)-acryloyl]-4-(3-piperidin-1-yl-propyl)-[1,4]diazepan-5-one
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | trans-3,4-Difluorocinnamic acid | HCID 2733300 | — |
| 반응물 | 1-[(E)-3-(3,4-Dichloro-phenyl)-acryloyl]-[1,4]diazepan-5-one | HCID 62044921 | — |
| 반응물 | 4-(3-Piperidin-1-yl-propyl)-[1,4]diazepan-5-one dihydrochloride | HCID 67080747 | — |
| 생성물 | 1-[(e)-3-(3,4-Difluoro-phenyl)-acryloyl]-4-(3-piperidin-1-yl-propyl)-[1,4]diazepan-5-one | HCID 68434944 | — |
반응 단계
In analogy to the procedure described in intermediate 1A, (E)-3,4-difluorocinnamic acid and 4-(3-piperidin-1-yl-propyl)-[1,4]diazepan-5-one-dihydrochloride (intermediate 4B, suspended in CH2Cl2 with 4 equivalent of Et3N) gave after purification on catridges, Si-Amine, 70 ml, 20 g (EtOAc) the title compound as a white powder. MS: 406.2 (MH+).
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US07632829B2 |
| 출처 데이터셋 | uspto-grants-2009_12 |
| ORD ID | ord-12012dab71db4d73a74ed26fc5bb68a6 |
| 출처 메모 | uspto-grants-2009_12 |